Biomarkers Market by Product, Type, Application & by Disease Indication - Global Forecast to 2020

In this report, the biomarkers market is segmented on the basis of product, type, application, disease indication, and geography. The product segments included in this report are consumables, services, software. The type segments included in this report are safety biomarkers, efficacy biomarkers, and validation biomarkers. The applications segments included in this report are diagnostics development, drug discovery and development, personalized medicine, disease risk assessment, and other applications. The disease indications segments included in this report are cancer, cardiovascular disorders, neurological disorders, immunological disorders, and other diseases.

The geographic segments included in this report are North America, Europe, Asia, and the Rest of the World (RoW).

The growth of this market is mainly driven by increasing healthcare expenditure, increase in R&D spending, increasing utility of biomarkers for diagnostics, increasing number of CROs, the low cost of clinical trials in developing countries, and new initiatives for biomarker research. The high growth potential in emerging markets and the increasing adoption of personalized medicine and companion diagnostics provides new growth opportunities to players in the biomarkers market.

A combination of bottom-up and top-down approaches were used to calculate the market sizes and growth rates of the global biomarkers market and its subsegments. Secondary information was used to identify overall revenue, geographic reach, and product portfolios of market players. Estimates of the biomarkers market segment revenues were validated through primary interviews. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates.

The report provides qualitative insights on key market shares, growth rates, and market drivers for important subsegments. It maps the market sizes and growth rates of each segment and identifies segments poised to witness rapid growth. The report includes company profiles and a competitive landscape of the biomarkers market. The company profiles include the financial performances, product portfolios, and developments of each company, whereas, the competitive landscape covers the growth strategies adopted by industry players over the last three years. The report also includes analyses of industry developments such as acquisitions, agreements, collaborations & partnerships; new product launches; and other developments.

Reasons to Buy the Report:

The report will enable both established firms and new entrants to gauge the pulse of the market and make important strategic growth decisions.

The report provides insights on the following:
‧ Product Development/Innovation: Product portfolios of the top players in the biomarkers market. Detailed insights on upcoming technologies, R&D activities, and new product launches in the biomarkers market
‧ Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of the leading players in the biomarkers market
‧ Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various biomarkers across geographies
‧ Market Diversification: Exhaustive information about new products, recent developments, and investments in the biomarkers market

TABLE OF CONTENTS

1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 MARKET SCOPE 18
1.3.1 MARKETS COVERED 18
1.3.2 YEARS CONSIDERED IN THE REPORT 19
1.4 CURRENCY 19
1.5 LIMITATIONS 19
1.6 STAKEHOLDERS 19
2 RESEARCH METHODOLOGY 20
2.1 MARKET SIZE ESTIMATION 21
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 24
2.3 MARKET SHARE ESTIMATION 25
2.3.1 KEY DATA FROM SECONDARY SOURCES 25
2.3.2 KEY DATA FROM PRIMARY SOURCES 25
2.3.3 ASSUMPTIONS FOR THE STUDY 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 31
4.1 LUCRATIVE OPPORTUNITIES IN THE GLOBAL BIOMARKERS MARKET 31
4.2 LIFE CYCLE ANALYSIS, BY REGION, 2015 33
5 MARKET OVERVIEW 34
5.1 INTRODUCTION 35
5.2 MARKET SEGMENTATION 35
5.2.1 BY PRODUCT 35
5.2.2 BY TYPE 35
5.2.3 BY APPLICATION 36
5.2.4 BY DISEASE INDICATION 36
5.3 MARKET DYNAMICS 37
5.3.1 DRIVERS 38
5.3.1.1 Increasing healthcare expenditure 38
5.3.1.2 Growth in R&D funding 38
5.3.1.3 Increasing utility of biomarkers for diagnostic purposes 39
5.3.1.4 Rising number of CROs and low cost for conducting clinical trials in developing countries 40
5.3.1.5 High prevalence of cancer 40
5.3.1.6 New initiatives for biomarker research 41
5.3.2 RESTRAINTS 42
5.3.2.1 High capital investment and low benefit-cost ratio 42
5.3.2.2 Poorly suited regulatory and reimbursement systems 42
5.3.2.3 High cost of tests 43
5.3.2.4 Technical issues related to sample collection and storage 43
5.3.3 OPPORTUNITIES 44
5.3.3.1 Personalized medicine 44
5.3.3.2 Companion diagnostics 45
5.3.3.3 Emerging economies 45
5.3.4 CHALLENGES 46
5.3.4.1 Proving clinical validity and utility of biomarker-based tests 46
6 BIOMARKERS MARKET, BY PRODUCTS 48
6.1 INTRODUCTION 49
6.2 CONSUMABLES 50
6.3 SERVICES 52
6.4 SOFTWARE 54
7 BIOMARKERS MARKET, BY TYPE 56
7.1 INTRODUCTION 57
7.2 SAFETY BIOMARKERS 58
7.3 EFFICACY BIOMARKERS 60
7.3.1 PREDICTIVE BIOMARKERS 63
7.3.2 SURROGATE BIOMARKERS 64
7.3.3 PHARMACODYNAMIC BIOMARKERS 66
7.3.4 PROGNOSTIC BIOMARKERS 67
7.4 VALIDATION BIOMARKERS 69
8 BIOMARKERS MARKET, BY APPLICATION 71
8.1 INTRODUCTION 72
8.2 DIAGNOSTICS DEVELOPMENT 73
8.3 DRUG DISCOVERY AND DEVELOPMENT 75
8.4 PERSONALIZED MEDICINE 77
8.5 DISEASE RISK ASSESSMENT 78
8.6 OTHER APPLICATIONS 80
9 BIOMARKERS MARKET, BY DISEASE INDICATION 82
9.1 INTRODUCTION 83
9.2 CANCER 84
9.3 CARDIOVASCULAR DISORDERS 86
9.4 NEUROLOGICAL DISORDERS 88
9.5 IMMUNOLOGICAL DISORDERS 90
9.6 OTHER DISEASES 92
10 BIOMARKERS MARKET, BY REGION 95
10.1 INTRODUCTION 96
10.2 NORTH AMERICA 99
10.2.1 U.S. 106
10.2.2 CANADA 112
10.3 EUROPE 118
10.4 ASIA 124
10.5 REST OF THE WORLD (ROW) 131
11 COMPETITIVE LANDSCAPE 137
11.1 INTRODUCTION 137
11.2 STRATEGIC OVERVIEW 137
11.3 MARKET SHARE ANALYSIS, BIOMARKERS MARKET 139
11.4 COMPETITIVE SITUATION AND TRENDS 140
11.4.1 ACQUISITIONS 141
11.4.2 AGREEMENTS, COLLABORATIONS, EXPANSION, JOINT VENTURES, AND PARTNERSHIPS 142
11.4.3 NEW PRODUCT AND SERVICE LAUNCHES 143
11.4.4 OTHER DEVELOPMENTS 144
12 COMPANY PROFILES 145
(Overview, Financials, Products & Services, Strategy, & Developments)*
12.1 INTRODUCTION 145
12.2 QIAGEN N.V. 146
12.3 PERKINELMER, INC. 149
12.4 MERCK & CO, INC. 152
12.5 BIO-RAD LABORATORIES, INC. 154
12.6 ENZO BIOCHEM, INC. 156
12.7 EKF DIAGNOSTICS HOLDINGS, INC. 159
12.8 MESO SCALE DIAGNOSTICS, LLC. 162
12.9 SINGULEX, INC. 164
12.10 BIOSIMS TECHNOLOGIES 166
12.11 CISBIO BIOASSAYS 168
12.12 SIGNOSIS, INC. 170

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

13 APPENDIX 172
13.1 INSIGHTS OF INDUSTRY EXPERTS 172
13.2 DISCUSSION GUIDE 173
13.3 OTHER DEVELOPMENTS 175
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 179
13.5 AVAILABLE CUSTOMIZATIONS 180
13.6 RELATED REPORTS 181